Cancer drug development faces three persistent problems: tumor resistance to therapies, high failure rates and costs of clinical trials due to difficulty identifying the right patients, and toxicity or delivery challenges that prevent promising drugs from reaching patients. Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF) is building a development strategy that integrates novel biology, advanced drug delivery, and artificial intelligence to tackle these issues simultaneously.
At the core of Onco-Innovations' approach is ONC010, a lead candidate that pairs a PNKP inhibitor with a nanoparticle delivery system. PNKP is a DNA Damage Response (DDR) target distinct from PARP, which has been a focus in the field. By targeting DNA repair pathways beyond PARP, the company aims to address resistance mechanisms that limit the effectiveness of existing therapies. The nanoparticle delivery system is intended to enhance drug delivery, potentially reducing toxicity and improving therapeutic outcomes.
Onco-Innovations is also incorporating AI through its Inka Health subsidiary and the SynoGraph causal AI platform. These tools are designed to support patient stratification, clinical trial design, and evidence generation, helping to identify the right patients for trials and reduce development costs. The combination of novel biology, delivery technology, and AI positions the company to address challenges that are often tackled separately in the industry.
According to the company, ONC010 is advancing through IND-enabling studies, manufacturing, and regulatory work. The integration of AI-enabled tools is intended to streamline development and improve the likelihood of success in clinical trials. As precision oncology increasingly relies on biomarker-driven therapies and smarter trial designs, companies that can integrate multiple emerging frontiers may be better positioned to overcome persistent development hurdles.
For more information, visit the company's newsroom at ibn.fm/ONNVF.
